Article Text
PDFReview
Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies
Abstract
Understanding of the natural history and basic biology of hepatitis B virus (HBV) has increased greatly in recent years. In view of this, the following are reviewed here: (a) recent advances in HBV biology pertinent to the rheumatic disease population; (b) the risks of HBV reactivation in patients with rheumatic disease undergoing immunosuppression; and (c) potential strategies to manage these risks.
- ALT, alanine aminotransferase
- anti-HBc, antibody to hepatitis B core antigen
- anti-HBs, antibody to hepatitis B surface antigen
- HBcAg, hepatitis B core antigen
- HBeAg, hepatitis B e antigen
- HBsAg, hepatitis B surface antigen
- HHBV, hepatitis B virus
- HCC, hepatocellular carcinoma
- IFN, interferon
- TNF, tumour necrosis factor
- hepatitis B virus
- biologic therapy
- immunosuppression